WO2002074232A2 - Antitumor compositions containing taxane derivatives - Google Patents

Antitumor compositions containing taxane derivatives Download PDF

Info

Publication number
WO2002074232A2
WO2002074232A2 PCT/IB2002/002239 IB0202239W WO02074232A2 WO 2002074232 A2 WO2002074232 A2 WO 2002074232A2 IB 0202239 W IB0202239 W IB 0202239W WO 02074232 A2 WO02074232 A2 WO 02074232A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
constituents
composition
neoplastic disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/002239
Other languages
English (en)
French (fr)
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of WO2002074232A2 publication Critical patent/WO2002074232A2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to combinations of taxol, Taxotere and their
  • Taxol Taxol, Taxotere and their analogues, which possess noteworthy antitumor
  • subject to be treated are between 1 and 10 mg/kg administered intraperitoneally
  • agents such as cyclophosphamide, isosfamide, melphalan, hexametyl-
  • melamine thiotepa or dacarbazine
  • antimetabolites such as pyrimidine
  • analogues for instance 5-fluarouracil and cytarabine, or its analogues such as 2-
  • flourodeoxycytidine or folic acid analogues such as methotrexate, idatrexate or
  • spindle poisons including vinca alkaloids such as vinblastine or
  • vincristine or their synthetic analogues such as navelbine, or estramustine or
  • taxoids such as etoposide or teniposide
  • epidophylloptoxins such as etoposide or teniposide
  • antibiotics such as
  • daunorubicine doxorubicin
  • bleomycin bleomycin or mitomycin
  • enzymes such as L-
  • topoisomerase inhibitors such as camptothecin derivatives
  • growth factor inhibitors such as interferons or interleukins.
  • haematopoietic type such as G-CSF or GM-CSF or certain interleukins with
  • Taxol Taxotere, their analogues or their combinations with other therapeutically
  • the invention relates to combinations of taxol, Taxotere
  • doxorubicin doxorubicin
  • cisplatin navelbine
  • camptothecin camptothecin
  • etoposide doxorubicin, cisplatin, navelbine, camptothecin, and etoposide.
  • This efficacy may be quantified, for example, by the log 10 cells killed, which is
  • T - C represents the time taken for the cells to grow, which is the mean
  • the efficacy of the combinations on solid tumors may be determined
  • mice The animals subjected to the experiment, generally mice.
  • tumors are mixed before being subjected to the various treatments and controls.
  • tumors are treated before being subjected to the various treatments and controls.
  • tumors are treated before being subjected to the various treatments and controls.
  • the selected animals are distributed at
  • Chemotherapy generally begins from 3 to 22 days after grafting,
  • the tumors are measured 2 or 3 times a week until the tumor reaches
  • the antitumor activity is determined in accordance with the different conditions
  • the antitumour activity is determined by the
  • chemotherapeutic agents such as cyclophosphamide (alkylating agent), 5-
  • fluorouracil antimetabolite
  • etoposide semisynthetic podophyllotoxin agent
  • vincristine vinca alkaloid
  • debenzoyl-N-t-butoxy-carbonyl-7-deoxy-8-desmethyl-7, 8-cyclopropataxotere (hereinafter acetocyclopropyl taxotere) with several chemotherapeutic agents.
  • agents such as doxorubicin (antibiotic), cisplatin (platinum coordination
  • mice bearing s.c. transplantable tumors were evaluated in mice bearing s.c. transplantable tumors.
  • the tumor model
  • CTI CTI index
  • the CTI represents the sum of the fractions of the lethal dose 10% (LD 10 )
  • a CTI of 1 indicates that only 50% of the LD 10
  • each single agent (or any of the ratios, 70:30, 40:60, etc ). can be used in
  • acetocyclopropyl taxotere had a log cell kill of 2.9 and doxorubicin-3.0.
  • HNTD of each single agent can be combined without additional toxicity.
  • mice were not
  • CPT-11 CPT-11 .
  • CTI of 0.6 indicates an important overlap in host toxicity.
  • doxorubicin or navelbine were well tolerated with a CTI of approximately 1.4,
  • the present invention also relates, therefore, to pharmaceutical compositions containing the combinations according to the invention.
  • the constituents of which the combination are composed may be any constituents of which the combination are composed.
  • compositions according to the invention are preferably compositions
  • compositions which can be administered parentally.
  • these compositions may be any compositions which can be administered parentally.
  • these compositions may be any compositions which can be administered parentally.
  • these compositions may be any compositions which can be administered parentally.
  • compositions for parental administration are generally
  • non-aqueous solutions or suspensions natural vegetable oils such as olive oil,
  • sesame oil or liquid petroleum or injectable organic esters such as ethyl oleate
  • the sterile aqueous solutions can consist of a solution of the
  • aqueous solutions are suitable for intravenous
  • isotonic for example with a sufficient amount of sodium chloride or glucose.
  • sterilization may be carried out by heating or by any other means which does not
  • the combinations may also take the form of
  • liposomes or the form of an association with carriers as cyclodextrins or
  • compositions for oral or intraperitoneal administration are preferably
  • the combinations according to the invention are especially useful in the treatment of cancers of the colon, breast, ovary or lung, as well as melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/IB2002/002239 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives Ceased WO2002074232A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/813,018 US6441026B1 (en) 1993-11-08 2001-03-21 Antitumor compositions containing taxane derivatives
US09/813,018 2001-03-21

Publications (1)

Publication Number Publication Date
WO2002074232A2 true WO2002074232A2 (en) 2002-09-26

Family

ID=25211230

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2002/002239 Ceased WO2002074232A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives
PCT/IB2002/000853 Ceased WO2002074289A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/000853 Ceased WO2002074289A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Country Status (19)

Country Link
US (1) US6441026B1 (https=)
EP (1) EP1478355B1 (https=)
JP (1) JP4467885B2 (https=)
CN (2) CN101590057A (https=)
AT (1) ATE355837T1 (https=)
AU (1) AU2002244877B2 (https=)
BR (1) BR0208274A (https=)
CA (1) CA2440160C (https=)
CY (1) CY1106582T1 (https=)
DE (1) DE60218751T2 (https=)
DK (1) DK1478355T3 (https=)
EA (1) EA006878B1 (https=)
ES (1) ES2282400T3 (https=)
HU (1) HUP0500478A2 (https=)
IL (1) IL157992A (https=)
MX (1) MXPA03008539A (https=)
PT (1) PT1478355E (https=)
SI (1) SI1478355T1 (https=)
WO (2) WO2002074232A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035034A3 (en) * 2002-10-16 2004-07-22 Ilex Products Inc Clofarabine and taxane chemotherapy combination
WO2004073719A1 (en) * 2003-02-21 2004-09-02 Pharmacia Italia S.P.A. A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
GB2440643A (en) * 2006-08-03 2008-02-06 Sanofi Aventis Antitumor composition comprising a taxotere derivative and herceptin

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
HRPK20041072B3 (hr) * 2002-05-17 2007-07-31 Aventis Pharma S.A. Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
ATE465205T1 (de) * 2005-12-05 2010-05-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
JP2010526159A (ja) * 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
PT2155255E (pt) 2007-05-09 2013-10-15 Nitto Denko Corp Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido
CN101730549B (zh) * 2007-05-09 2015-12-09 日东电工株式会社 与铂类药物结合的聚合物
US20080279778A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
KR20130140033A (ko) * 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
CN102241648B (zh) * 2011-01-31 2016-08-03 沈阳东星医药科技有限公司 抗多药耐药紫杉烷类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1992019765A1 (en) 1991-05-08 1992-11-12 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5284865A (en) 1991-09-23 1994-02-08 Holton Robert A Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (en) * 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035034A3 (en) * 2002-10-16 2004-07-22 Ilex Products Inc Clofarabine and taxane chemotherapy combination
WO2004073719A1 (en) * 2003-02-21 2004-09-02 Pharmacia Italia S.P.A. A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
GB2440643A (en) * 2006-08-03 2008-02-06 Sanofi Aventis Antitumor composition comprising a taxotere derivative and herceptin
GB2440643B (en) * 2006-08-03 2011-04-06 Sanofi Aventis Antitumor combinations comprising taxane derivatives

Also Published As

Publication number Publication date
ES2282400T3 (es) 2007-10-16
IL157992A (en) 2008-08-07
JP2004536790A (ja) 2004-12-09
CN101590057A (zh) 2009-12-02
EP1478355B1 (en) 2007-03-07
SI1478355T1 (sl) 2007-08-31
US20020031505A1 (en) 2002-03-14
US6441026B1 (en) 2002-08-27
EA200301047A1 (ru) 2004-06-24
CA2440160A1 (en) 2002-09-26
CY1106582T1 (el) 2012-01-25
MXPA03008539A (es) 2004-08-11
DE60218751D1 (de) 2007-04-19
CN1536995A (zh) 2004-10-13
CA2440160C (en) 2011-07-05
AU2002244877B2 (en) 2006-07-20
DK1478355T3 (da) 2007-07-02
EA006878B1 (ru) 2006-04-28
DE60218751T2 (de) 2007-11-22
HUP0500478A2 (hu) 2005-08-29
WO2002074289A3 (en) 2004-09-02
JP4467885B2 (ja) 2010-05-26
ATE355837T1 (de) 2007-03-15
EP1478355A2 (en) 2004-11-24
WO2002074289A2 (en) 2002-09-26
BR0208274A (pt) 2004-07-13
PT1478355E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
US5908835A (en) Anti-tumor compositions containing taxane derivatives
US6441026B1 (en) Antitumor compositions containing taxane derivatives
AU2002244877A1 (en) Antitumor compositions containing taxane derivatives
EP1977753A1 (en) Combined preparation comprising anthracycline derivatives
Kelly Irinotecan in small-cell lung cancer: current data
HK1138185A (en) Antitumor compositions containing taxane derivatives
HK1096867A (en) Combined preparations comprising anthracycline derivatives
HK1096538A (en) Combined preparations comprising anthracycline derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWW Wipo information: withdrawn in national office

Ref document number: 2002309166

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP